Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

Guidance on the use of paclitaxel in the treatment of ovarian cancer.

BIBLIOGRAPHIC SOURCE(S)

  • National Institute for Clinical Excellence (NICE). Guidance on the use of paclitaxel in the treatment of ovarian cancer. London (UK): National Institute for Clinical Excellence (NICE); 2003 Jan. 19 p. (Technology appraisal guidance; no. 55).

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Guidance on the use of taxanes for ovarian cancer. London (UK): National Institute of Clinical Excellence (NICE); 2000 May. (Technology appraisal 3).

BRIEF SUMMARY CONTENT

 
RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

  • It is recommended that paclitaxel in combination with a platinum-based compound or platinum-based therapy alone (cisplatin or carboplatin) are offered as alternatives for first-line chemotherapy (usually following surgery) in the treatment of ovarian cancer.
  • The choice of treatment for first-line chemotherapy for ovarian cancer should be made after discussion between the responsible clinician and the patient about the risks and benefits of the options available. In choosing between treatment with a platinum-based compound alone or paclitaxel in combination with a platinum-based compound, this discussion should cover the side-effect profiles of the alternative therapies, the stage of the woman's disease, the extent of surgical treatment of the tumour, and disease-related performance status.
  • When relapse occurs after an initial (or subsequent) course of first-line chemotherapy, additional courses of treatment with the chosen chemotherapy regimen (re-challenge therapy) should be considered if the initial (or previous) response has been adequate in extent and duration. Once the tumour fails to respond adequately to the chosen first-line regimen, different treatment options should be considered as part of second-line therapy (see below).
  • Paclitaxel is not recommended as second-line (or subsequent) therapy in women with ovarian cancer who have received the drug as part of their first-line treatment. For women who have not received paclitaxel as part of first-line treatment, it should be considered as one option alongside other drugs licensed for second-line treatment of ovarian cancer.
  • Only oncologists specialising in ovarian cancer should supervise the provision of chemotherapy in ovarian cancer.

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of evidence supporting the recommendations is not specifically stated.

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • National Institute for Clinical Excellence (NICE). Guidance on the use of paclitaxel in the treatment of ovarian cancer. London (UK): National Institute for Clinical Excellence (NICE); 2003 Jan. 19 p. (Technology appraisal guidance; no. 55).

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2000 May (revised 2003 Jan)

GUIDELINE DEVELOPER(S)

National Institute for Health and Clinical Excellence (NICE) - National Government Agency [Non-U.S.]

SOURCE(S) OF FUNDING

National Institute for Health and Clinical Excellence (NICE)

GUIDELINE COMMITTEE

Appraisal Committee

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Committee Members: Professor R L Akehurst, Dean, School of Health Related Research, Sheffield University; Professor David Barnett (Chair) Professor of Clinical Pharmacology, University of Leicester; Professor Sir Colin Berry, Professor of Morbid Anatomy St Bartholomew's and Royal London School of Medicine; Dr Sheila Bird, MRC Biostatistics Unit, Cambridge; Professor Martin Buxton, Director of Health Economics Research Group Brunel University; Dr Karl Claxton, Lecturer in Economics, University of York; Professor Sarah Cowley, Professor of Community Practice Development Kings College, London; Mr Chris Evennett, Chief Executive Mid-Hampshire Primary Care Group; Professor Terry Feest, Clinical Director and Consultant Nephrologist, Richard Bright Renal Unit and Chairman of the UK Renal Registry; Professor Gary Ford, Professor of Pharmacology of Old Age / Consultant Physician, Wolfson Unit of Clinical Pharmacology University of Newcastle; Mrs Sue Gallagher, Chief Executive, Merton, Sutton and Wandsworth Health Authority; Dr Trevor Gibbs, Head, Global Clinical Safety & Pharmacovigilance GlaxoSmithKline; Mr John Goulston, Director of Finance, Barts & the London NHS Trust; Professor Philip Home, Professor of Diabetes Medicine, University of Newcastle; Dr Terry John, General Practitioner, The Firs, London; Dr Diane Ketley, Research into Practice Programme Leader NHS Modernisation Agency; Dr Mayur Lakhani, General Practitioner, Highgate Surgery, Leicester and Lecturer, University of Leicester Mr M Mughal, Consultant Surgeon, Chorley and South Ribble NHS Trust; Mr James Partridge, Chief Executive, Changing Faces; Professor Philip Routledge, Professor of Clinical Pharmacology, University of Wales; Professor Andrew Stevens (Vice Chairman) Professor of Public Health, University of Birmingham; Dr Cathryn Thomas, General Practitioner, Senior Lecturer Department of Primary Care and General Practice University of Birmingham

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Committee members are asked to declare any interests in the technology to be appraised. If it is considered there is a conflict of interest, the member is excluded from participating further in that appraisal.

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Guidance on the use of taxanes for ovarian cancer. London (UK): National Institute of Clinical Excellence (NICE); 2000 May. (Technology appraisal 3).

GUIDELINE AVAILABILITY

AVAILABILITY OF COMPANION DOCUMENTS

The following are available:

Print copies: Available from the National Health Service (NHS) Response Line 0870 1555 455. ref: N0186. 11 Strand, London, WC2N 5HR.

Additionally, Audit Criteria are available in Appendix D of the original guideline document.

PATIENT RESOURCES

The following is available:

  • Guidance on the use of paclitaxel in the treatment of ovarian cancer. Information for the public. London (UK): National Institute for Health and Clinical Excellence (NICE); 2003 Jan. 8 p. (Technology appraisal 55).

Electronic copies: Available in Portable Document Format (PDF) from the National Institute for Health and Clinical Excellence (NICE) Web site.

Print copies: Available from the Department of Health Publications Order Line 0870 1555 455. ref: N0187. 11 Strand, London, WC2N 5HR.

Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.

NGC STATUS

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo